Novavax

$103.62
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$7.27 (+7.63%) Today
+$1.02 (+0.99%) As of 8:00 PM EST after-hours

Why Robinhood?

You can buy or sell Novavax and other stocks, options, and ETFs commission-free!

About NVAX

Novavax, Inc. Common Stock, also called Novavax, is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD. The listed name for NVAX is Novavax, Inc. Common Stock.

CEO
Stanley C. Erck
Employees
165
Headquarters
Gaithersburg, Maryland
Founded
1987
Market Cap
6.53B
Price-Earnings Ratio
Dividend Yield
Average Volume
4.03M
High Today
$103.88
Low Today
$94.67
Open Price
$95.32
Volume
3.79M
52 Week High
$189.40
52 Week Low
$3.65

Collections

Digestible Financial News

Jack Kramer & Nick Martell

Managing Editors of News & Snacks at Robinhood Financial LLC

NVAX News

MarketWatch3h

I’ve already been injected with a COVID vaccine. This is why I’m cheering for the Novavax underdog

The first question that came to my friends’ minds was whether I’d really thought about the possible dangers. Two of them, more focused on worldly matters, asked

NVAX Earnings

-$3.21
-$1.56
$0.08
$1.73
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 11, After Hours

You May Also Like